Bevacizumab Combination In Non-Small Cell Lung Cancer

The FDA has approved bevacizumab (Avastin, Genentech) for use in combination with carboplatin and paclitaxel chemotherapy for the first-line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer, the most common type of lung cancer.

In a phase 3 study, bevacizumab plus chemotherapy resulted in a 25% improvement in overall survival, compared with chemotherapy alone.

In 2004, the FDA approved the drug for the first-line or second-line treatment of metastatic colon or rectal carcinoma in combination with IV 5-fluorouracil-based chemotherapy.